On March 31, 2025, Dogwood Therapeutics, Inc. announced financial results for 2024 and provided a business update. The company recently dosed the first patient in the Halneuron Chemotherapy Induced Neuropathic Pain (CINP) Phase 2b trial. We anticipate interim data in the fourth quarter of 2025. Dogwood also recently converted all of its outstanding $19.5 million loan into equity, thereby improving the company's balance sheet. The company is continuing to explore external funding and/or partnerships to advance IMC-2 into Phase 2b development as a treatment for Long Covid and IMC-1 as a treatment for fibromyalgia.
